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Over the past 15 years, three new classes of drugs, glucagon-like peptide-1 (GLP-1) receptor
agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors and sodium glucose cotransporter-2 (SGLT-2)
inhibitors have been approved to treat type 2 diabetes based on effects on glycemic control.
Although large randomized controlled trials have played an important role in characterizing the
efficacy and safety of these agents on a population level, questions remain about how best to
individualize therapy and target the “right” medicine to the “right” patient. In contrast, few medi-
cines have been approved to treat diabetic kidney disease and initiatives have been launched on
both sides of the Atlantic to facilitate the development of effective personalized medicines for
the treatment of diabetic kidney disease. Increasingly, “omics,” imaging and other biomarkers
will be used to match patients with therapies to which they are likely to respond best. This
review addresses regulatory considerations related to precision medicine, draws lessons learned
from other therapeutic areas and discusses efforts undertaken by the European (EMA) and
United States (FDA) to facilitate the development of such therapies. Moving forward, an inte-
grated approach that makes use of predictive preclinical models, innovative trial designs, obser-
vational “real-world” data and novel statistical methodologies will likely be needed to
complement inherently smaller RCTs conducted in more selected populations. Patient involve-
ment will also be critical. Regulatory agencies are ready to engage in such approaches.
KEYWORDS
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1 | INTRODUCTION
In the past 15 years, three new classes of drugs, glucagon-like peptide-
1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors
and sodium glucose cotransporter-2 (SGLT-2) inhibitors have been
approved for the treatment of diabetes based on their ability to lower
glucose levels in patients with type 2 diabetes.1 Over this time period,
another drug, rosiglitazone, which had been approved based on effects
on glycemic control, was ultimately withdrawn from the European mar-
ket and its use restricted in the United States because of concerns over
its cardiovascular (CV) safety.2 Thus, with uncertainties remaining over
the macrovascular benefits—and even potential harms—of glucose-
lowering drugs, the US Food and Drug Administration (FDA) issued
guidance in 2008 on how sponsors should demonstrate that new anti-
diabetic agents for type 2 diabetes do not increase cardiovascular risk
to an unacceptable extent.3 It should be noted that in Europe, cardio-
vascular outcome trials (CVOT) are not required for new antidiabetic
agents, although at the time of approval, CV (and other) harms should
nevertheless be excluded.4,5 Since the introduction of the FDA guid-
ance in 2008, a large number of CVOTs have been conducted to assess
the cardiovascular risk of antidiabetic agents.1 These trials enrolled
large populations and included, in total, over 100 000 patients with
type 2 diabetes often at high CV risk to allow more efficient evaluation
of CV safety. They demonstrated the CV safety of DPP4 inhibitors,
GLP-1 agonists and SGLT-2 inhibitors and even important benefits for
some GLP-1 agonists and SGLT-2 inhibitors. Although these mega-trials
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have played an important role in characterizing the efficacy and safety
of these new interventions on a population level, a marked heterogene-
ity in response at the individual level was observed.6–8 Questions thus
remain about how to individualize therapy and select the “right” drug
for the “right” patient.
In contrast to this experience, no medicine has been approved by
the FDA or European Medicines Agency (EMA) to treat diabetic kidney
disease within over 15 years. Although recent CVOTs raise hope that
some of the new antidiabetic medicines may also provide important
renal benefits, there is widespread recognition that better tools and a
better understanding of diabetic kidney disease is needed to facilitate
drug development for diabetic kidney disease. This includes the need to
identify different subgroups of patients with the disease who may be
more likely to progress and/or who are more likely to respond benefi-
cially to certain treatments. Indeed, projects, like the Innovative Medi-
cines Initiative Biomarker Enterprise to Attack Diabetic Kidney Disease
(www.beat-dkd.eu) and the Kidney Precision Medicine Project (www.
kpmp.org) have been initiated in Europe and the United States, respec-
tively, to facilitate the development of effective personalized medicines
for the treatment of diabetic kidney disease.
This landscape, which arguably includes both extremes—a relative
abundance of medicines approved to improve glycemic control in type
2 diabetes and questions related to how to choose from among them,
as well as a paucity of medicines approved to slow the progression of
diabetic kidney disease-highlights the need for more targeted or per-
sonalized treatment approaches to maximize the benefit-to-harm ratio
of approved therapies and to facilitate the development of new ones.
Such an approach reflects an approach that is increasing being adopted
in other areas of medicine, in particular oncology. This review addresses
regulatory considerations related to precision medicine, draws lessons
learned from other therapeutic areas, and discusses efforts undertaken
by the EMA and FDA to facilitate the development of such therapies.
2 | PRECISION MEDICINE AND THE
REGULATORY SYSTEM
Today's regulatory systems aim to ensure the quality and effectiveness/
efficacy of medicines and a positive benefit-risk profile. While the qual-
ity of the medicine is essentially the summed assessment of critical
product features (eg, potency, product stability, purity), the benefit-risk
is a summed function of what the medicine brings to the patient (eg,
pharmacodynamics) and what the patient brings to the medicine (eg,
renal function, genotype, patient adherence). There is growing evidence
that what the patient brings to the medicine is critical to patient out-
comes, both in terms of efficacy/effectiveness and safety.
Finding the best patient-therapy pair, or precision medicine, is not a
new concept. Physicians have always endeavored to match available
remedies to patients, considering the characteristics of the patient, the
characteristics of the drug, and ideally the patient's values and priori-
ties. But advances in pharmacogenomic science, biomarker discovery,
as well as the identification of other signatures of therapy response
have paved the way for greater sophistication in finding the best
patient-therapy pair. Moreover, increasingly caregivers and clinicians
involve willing patients in shared decision-making, choosing a therapy
based on (expected) outcomes that are most relevant to these patients.
Patients and regulators may have mostly similar values with regards to
major drug effects of antidiabetic drugs, but do differ in the value they
attach to minor short-term (adverse) drug effects.9 Whereas patients
are already involved in a range of activities at the EMA and FDA, a
European public private partnership project, IMI-PREFER (https://
www.imi-prefer.eu/) investigates how and when to include patient-
preference in decision-making during the drug life cycle. Moving for-
ward, regulatory systems should help ensure that these best patient-
therapy pairs can be identified and brought together. Some products
are relatively forgiving, (eg, there is a large range between doses/expo-
sures that cause benefit and those that cause harm) and can be used in
a broad swath of patients with a disease. Other products, however,
need careful targeting, monitoring and follow-up, because a “mismatch”
may result in a harm that outweighs the benefit. Examples include met-
formin (diabetes) in patients with severe renal impairment or abacavir
(HIV) in patients known to carry the HLA-B*5701 allele. The drug label,
also known as the Summary of Product Characteristics (SmPC) in
Europe, is meant to help prescribers identify the best patient-therapy
match. For example, the SmPC for rosuvastatin indicates that for
patients with SLCO1B1 (OATP1B1) and/or ABCG2 (BCRP) genetic
polymorphisms in these transporter proteins there is a risk of increased
rosuvastatin exposure and a lower daily dose is recommended.10 The
SmPC for clopidogrel describes that in patients who are poor CYP2C19
metabolisers, at recommended doses clopidogrel forms less of its active
metabolite and has a smaller effect on platelet function.11
There are, however, many methodological challenges associated
with determining the best patient-therapy match; we discuss some of
these challenges in the next section.
3 | NEW CLINICAL TRIAL DESIGNS FOR
PRECISION MEDICINE IN REGULATORY
CONTEXT
Regulators are well-versed in evaluating drug effects at a population
level based on randomized (double-blind) controlled trials (RCT).
Robust findings in well-conducted RCTs allow regulators to draw con-
clusions about a drug's benefit-to-harm ratio with reasonable certainty
for a population similar to the one studied in the trial. Typically, a drug
is approved based on a finding in the overall population, for example,
by demonstrating that in the trial population the mean effect in the
test arm of the trial is larger than in the placebo arm or at least non-
inferior to an active control arm, and if adverse effects do not off-set
the observed benefit.
In contrast to this population-based approach, precision medicine
makes use of an increased understanding of disease biology to a priori
define patient groups that are more likely to respond positively or
negatively to a treatment; that is, improve the patient-therapy match.
Predictive biomarkers are used to individualize treatment to patients
with a specific disease expression or initial treatment response.12 To
date, this approach has been most widely used in oncology with thera-
pies targeted to, and defined by genetic mutations, for example,
Human Epithelial Growth Factor Receptor 1 (HER1) mutations
(trastuzumab),13 programmed death ligand-1 (PDL-1) expression
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(pembrolizumab)14 and BRAF mutations (vemurafenib).15 In the major-
ity of these oncology development programs, translational research
and exploratory clinical trials informed the pivotal registration studies.
In other fields, dynamic or response biomarkers thought to predict the
long-term benefit or harms of treatment are being explored to target
medicines to populations more likely to derive benefit. For example, in
the SONAR trial, patients with diabetic kidney disease were random-
ized to continued active therapy or placebo if they showed a response
in albuminuria (>30% decrease) to an initial 6 weeks of atrasentan
treatment; some patients who were biomarker “negative” were also
enrolled for reasons discussed below.16 Such dynamic or response
biomarkers are needed to individualize treatment.17
While focusing clinical trial enrollment on patients more likely to
respond positively to treatment has obvious advantages, often it is
unclear how well the predictive or response biomarker performs in
identifying this population, and hence, regulators are often interested
in treatment effects in patients who are biomarker negative. Do
patients without a certain biomarker response truly not benefit in
terms of (long-term) clinical endpoints? Is there really no treatment
response in the biomarker negative population? Moreover, rarely does
a biomarker fully discriminate between responder and non-responder
patients. In other words, the sensitivity and specificity of the bio-
marker is seldom 100%. Hence, unless there are compelling data or
strong scientific rationale for concluding that biomarker negative
patients are unlikely to respond to a treatment, regulators encourage
the inclusion of marker-negative patients in the trial; the size/propor-
tion of the population included in the trial depends on the level of cer-
tainty in the performance of the biomarker or proposed cut-off in
identifying responders. In the SONAR trial in patients with diabetic
kidney disease, this issue was addressed by including more than 1000
patients with less than a 30% reduction in albuminuria; that is,
hypothesized non-responders. Randomization was also stratified
according to prespecified albuminuria response strata, with the objec-
tive of identifying a minimum albuminuria response threshold associ-
ated with a beneficial effect of treatment.16
Indeed, the experience in oncology teaches us that even when
patients with various biomarker expression levels are included in a
trial, a clear cut-off may not be easy to establish. For example, the
level of tumour programmed death-1 (PD-1) expression impacted the
effect of nivolumab + ipilimumab in the setting of unresectable meta-
static melanoma, but the impact was inconsistent across various cut-
offs. Given these findings, the indication in the SmPC indicates that
an increase in progression free survival and overall survival is estab-
lished only in patients with low (<1%) tumour PD-1 expression.18
Not surprisingly, the EMA guideline for anticancer European regu-
latory guidelines, reflects on the approach to developing targeted ther-
apies, with preferably prospective validation of biomarkers identified in
explorative studies or post hoc analyses.19 A thorough understanding
of the biology is a given. Enrichment designs (only biomarker positive
patients), stratified design (randomization based on biomarker expres-
sion, like in the SONAR trial) and adaptive enrichment designs (where
after an interim analysis randomization can be restricted to a
biomarker-positive population only) may be efficient ways for deter-
mining the benefit-risk in the biomarker-positive population. There is a
caveat though, that is that these enrichment designs may be non-
informative on the biomarker-negative population.20 As described else-
where in this issue of the Journal, platform, basket and umbrella trials
may offer additional innovative study designs for evidence generation
in the setting of precision-medicine.21 In addition, observational “real-
world” data may be increasingly considered to provide further evidence
postapproval.22 Finally, multiple smaller trials with clearly defined
patient populations could be used to test specific treatments or combi-
nations at various dose levels more appropriately than performing sub-
group analyses in large clinical trials. Ideally, these trials would use a
standardized data collection that allows future meta-analytical
approaches to answer questions that are relevant to a more general
population, provided a willingness to share data among different
parties.23 Regulatory experience remains, however, limited and there
are many methodological challenges for which regulators, industry, and
academic methodologists will need to collaborate in finding solutions.
Clearly, as Eichler and Sweeney write “…the randomised controlled trial
must adapt and evolve to respond to a changing environment….”23
4 | EUROPEAN AND USA REGULATORY
TOOLS TO SUPPORT USE OF NOVEL
METHODOLOGIES IN DRUG DEVELOPMENT
In Europe, biomarkers are qualified for a certain context of use, that
is, to support drug development or regulatory decision-making. Inter-
ested parties, often consortia or companies and academia can apply at
the Scientific Advice Working Party for “qualification of novel meth-
odologies.”24 This procedure can result in “qualification advice” or a
“qualification opinion.” The latter is an endorsement of the Committee
of Human Medicinal Products that the novel methodology, that is,
biomarker, may be used in a certain clearly defined context. For exam-
ple, to enrich a study population based on a biomarker or use a patient
reported outcome as a clinical endpoint (see Figure 1). A large propor-
tion of the qualification procedures focus on development of different
type of biomarkers; mostly protein and imaging biomarkers that are
developed primarily for use of evaluating clinical safety, as tool for
enrichment or to be used as endpoints. Another major set of proce-
dures focuses on development of patient reported outcomes and clini-
cal scores again in the context of use as endpoint or for enrichment
purposes to detect more responsive/at risk study populations. Finally,
a group of diverse procedures ranges from systems biology
approaches, big data to product-device methods that could be applied
throughout the drug development context. The data needed to qualify
the biomarker is highly dependent on the intended (context of ) use. A
qualification opinion is published on the website of the European
Medicines Agency and subject to a 2-month consultation procedure,
where interested parties may submit their views on a qualification. It
is expected that in the setting of precision medicine this procedure
may be sought more frequently by interested parties to improve the
pairing of patient and therapy.
The US FDA also has a Drug Development Tool (DDT) Qualifica-
tion Program that qualifies biomarkers, clinical outcome assessments
(COA) and animal models for a specific context of use in drug develop-
ment.25 As in Europe, qualification of the drug development tool
enables sponsors to use the tool in the qualified context of use during
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drug development without requesting that the regulatory body recon-
firm its suitability for the qualified context of use. The process for
qualification of drug development tools is changing in the United
States because of recent legislation titled the “21st Century Cures
Act.” This legislation formally establishes a multi-step step process for
qualification, consisting of three submissions to the qualification pro-
gram: a Letter of Intent, a Qualification Plan and a Full Qualification
Package. The new legislation also includes transparency provisions
that apply to both requestors' submissions and FDA's formal written
determinations on these submissions.25
Mechanisms also exist to enable better collaboration between
FDA and EMA on products in development or under review in both
regulatory regions. The EMA and FDA hold regular teleconferences
focusing on special topics and therapeutic areas. Existing workgroups
(referred to as “clusters”) focus on rare diseases, pediatric drug devel-
opment and pharmacogenomics, among other areas. Sponsors can
also seek parallel scientific advice from FDA and EMA on issues
related to the development phase of a new product. These platforms,
as well as others allow regulators to exchange information and discuss
issues affecting a drug development program and/or more general
issues affecting the development of medicines. Precision medicine
and the ability to identify, select and test drugs in the most responsive
patient populations are frequent topics during these discussions.
Disease-specific meetings and research consortia also provide an
opportunity for regulators from around the world to meet and interact
with the larger community on issues related to the development of
more targeted therapies.26
5 | SUMMARY AND CONCLUSION
Precision medicine presents both opportunities and challenges. Pro-
grams, such as the “qualification of novel methodologies” procedure
at the EMA and the Drug Development Tools Qualification Program
at the FDA are intended to support the development of tools that can
be used to expedite the development of new therapies and potentially
facilitate the development of much needed precision medicines. Mov-
ing forward, an integrated approach that makes use of predictive pre-
clinical models, innovative trial designs, observational “real-world”
data and novel statistical methodologies will likely be needed to com-
plement inherently smaller RCTs conducted in more selected popula-
tions. The speed at which we develop these medicines will depend in
large part on the willingness of various stakeholders to share individ-
ual patient data, be it from trials or observational data sets. Patient
involvement, and understanding of patient preferences towards dif-
ferent drug effects, will also be critical.
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